Yu-te Wu

Comparing the Response Rates for Superiority, Noninferiority and Equivalence Testing with Multiple-to-One Matched Binary Data

Mengdie Yuan, M. Shen, Xiaoyu Dong, 2013, Journal of biopharmaceutical statistics.

FDA Approval Summary: Selinexor for Relapsed or Refractory Diffuse Large B-Cell Lymphoma.

R. Pazdur, Y. Kasamon, M. Theoret, 2021, The oncologist.

Sample size for post‐marketing safety studies based on historical controls

R. Makuch, Yu-te Wu, Robert W. Makuch, 2010, Pharmacoepidemiology and drug safety.

Detecting Rare Adverse Events in Postmarketing Studies: Sample Size Considerations

Robert W. Makuch, R. Makuch, Yu-te Wu, 2006 .

Meta-analysis of a possible signal of increased mortality associated with cefepime use.

Charles K. Cooper, George Rochester, S. Nambiar, 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Association Between Changes in CMS Reimbursement Policy and Drug Labels for Erythrocyte-Stimulating Agents With Outcomes for Older Patients Undergoing Hemodialysis Covered by Fee-for-Service Medicare.

Mark S Levenson, Kimberly A Smith, A. Thompson, 2016, JAMA internal medicine.